Key metrics and charts across all fundamental categories.
Stock price and market valuation
GMED trades at $79.19, a 8.2% increase year-over-year. Market capitalization stands at $10.72B, up 7.1% from the prior year. Track GMED price trends and market cap history to understand how the market values this company over time.
Revenue and earnings growth across quarters
$3.10B in TTM revenue grew 23.5% YoY, reaching $759.85M last quarter. TTM EBITDA of $813.82M on operating income of $150.39M shows growth is flowing through. Net income of $586.71M TTM confirms the company is converting revenue into profit. Revenue is growing at a healthy pace — a signal to hold.
Assets, cash, debt, and leverage
Price multiples and return ratios
At 18.3x P/E, the stock trades in line with market averages — fairly valued. P/S of 3.5x and P/B of 2.3x provide additional context. Assess whether the current multiple is justified by the company's growth and profitability trajectory.
Operating efficiency and return metrics
Op. margin of 19.8% is up 3.6% YoY — cost efficiency is improving. Net margin at 16.4% and gross margin of 69.2%. ROE of 12.4% shows the company generates solid returns on shareholder equity.
Free cash flow, earnings quality, and capital allocation
FCF of $162.75M on $202.36M in operating cash flow. The FCF / Net Income ratio of 0.3x indicates partial cash conversion — earnings quality needs attention. Cash reserves of $560.95M provide financial flexibility.
